At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 190 enrolled
Drug / intervention
Etoricoxib + Cyanocobalamin fixed dose +1 moredrug
Likely dose
Etoricoxib + Cyanocobalamin fixed dose 90 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of the Fixed-Dose Combination of Etoricoxib/Cyanocobalamin Versus Etoricoxib in the Treatment of Patients with Acute Low Back Pain
In Brief
A Phase 3 clinical trial evaluating Etoricoxib + Cyanocobalamin fixed dose and Etoricoxib fixed dose for Acute Low-back Pain. Completed, enrolled 190 participants across 1 site.
Detailed Summary
Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and safety of the Fixed-Dose Combination of Etoricoxib/Cyanocobalamin Versus Etoricoxib in Patients With Acute Low Back Pain
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Low-back Pain
CountriesMexico
Collaborators--
Timeline
Phase 3CompletedFinished
20252026
Enrollment StartApr 2024
First PostedJul 2024
Primary CompletionOct 2024
Study CompletionOct 2024
TodayJul 2026
First PostedJul 24, 2024
Enrollment StartApr 26, 2024
Primary CompletionOct 4, 2024
Study CompletionOct 11, 2024
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 1.9 years ago
Interventions
Etoricoxib + Cyanocobalamin fixed dosedrug
One tablet of 90 mg / 0.50 mg a day
Etoricoxib fixed dosedrug
One pill of 90 mg a day